Loading
New drugs that destroy cancer proteins are usually too big to enter the brain. Making much smaller versions could bring this approach to brain tumours.
Bifunctional degraders typically exceed the size and polarity limits for passive brain entry, whereas molecular glues such as the thalidomide analogues are small and drug-like, and brain-penetrant glue degraders have been reported in neuroscience programmes. Applying glue chemistry to brain tumour dependencies, including transcription factors and fusion oncoproteins, would open targets that current chemistry cannot reach in the brain.
Shares C4 Therapeutics, Kymera Therapeutics, Monte Rosa Therapeutics, AI-driven drug & target discovery.
Shares C4 Therapeutics, Kymera Therapeutics, Monte Rosa Therapeutics, Nurix Therapeutics.
Shares Kymera Therapeutics, Monte Rosa Therapeutics, AI-driven drug & target discovery, The undruggable drivers.
Shares Kymera Therapeutics, Nurix Therapeutics, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares C4 Therapeutics, Kymera Therapeutics, Monte Rosa Therapeutics, Nurix Therapeutics.
Shares Kymera Therapeutics, Nurix Therapeutics, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares Blood-brain barrier (BBB), The brain: barrier and sanctuary, Glioma & glioblastoma.
Shares C4 Therapeutics, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).